Nkarta (NKTX) Gains from Investment Securities (2019 - 2026)
Nkarta's quarterly Gains from Investment Securities came in at $1.3 million in Q1 2026, up 66.78% year-on-year from $778078.0 in Q1 2025, and down 87.91% quarter-over-quarter from $10.7 million in Q4 2025.
Nkarta has reported Gains from Investment Securities for 8 years, with the latest figure at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 66.78% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 66.78% YoY), and the FY2025 full-year result was $10.7 million, up 18.39% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $1.3 million, down from $10.7 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $10.7 million in Q4 2025, with the low at $281206.0 in Q1 2024.
- Average Gains from Investment Securities over 5 years is $3.8 million, with a median of $1.6 million recorded in 2022.
- Peak annual rise in Gains from Investment Securities reached 6301.54% in 2022, while the deepest fall reached 86.49% in 2022.
- Tracing NKTX's Gains from Investment Securities over 5 years: stood at $5.5 million in 2022, then increased by 21.69% to $6.7 million in 2023, then surged by 35.03% to $9.1 million in 2024, then gained by 18.39% to $10.7 million in 2025, then sank by 87.91% to $1.3 million in 2026.
- The last three Gains from Investment Securities figures came in at $1.3 million (Q1 2026), $10.7 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.30 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 10.74 Mn |
| Dec 31, 2025 | 10.74 Mn |
| Sep 30, 2025 | 4.45 Mn |
| Sep 30, 2025 | 4.45 Mn |
| Jun 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | 4.40 Mn |
| Mar 31, 2025 | 778,078.00 |
| Mar 31, 2025 | 778,078.00 |
| Dec 31, 2024 | 9.07 Mn |
| Dec 31, 2024 | 9.07 Mn |
| Sep 30, 2024 | 9.10 Mn |
| Sep 30, 2024 | 9.10 Mn |
| Jun 30, 2024 | 326,848.00 |
| Jun 30, 2024 | 326,848.00 |
| Mar 31, 2024 | 281,206.00 |
| Mar 31, 2024 | 281,206.00 |
| Dec 31, 2023 | 6.72 Mn |
| Dec 31, 2023 | 6.72 Mn |
| Sep 30, 2023 | 7.13 Mn |
| Sep 30, 2023 | 7.13 Mn |
| Jun 30, 2023 | 503,639.00 |
| Jun 30, 2023 | 503,639.00 |
| Mar 31, 2023 | 700,000.00 |
| Mar 31, 2023 | 700,000.00 |
| Dec 31, 2022 | 5.52 Mn |
| Dec 31, 2022 | 5.52 Mn |
| Sep 30, 2022 | 565,915.00 |
| Sep 30, 2022 | 565,915.00 |
| Jun 30, 2022 | 1.64 Mn |
| Jun 30, 2022 | 1.64 Mn |
| Mar 31, 2022 | 1.01 Mn |
| Mar 31, 2022 | 1.01 Mn |
| Dec 31, 2021 | 4.20 Mn |
| Dec 31, 2021 | 4.20 Mn |
| Sep 30, 2021 | 4.19 Mn |
| Sep 30, 2021 | 4.19 Mn |
| Jun 30, 2021 | 4.29 Mn |
| Jun 30, 2021 | 4.29 Mn |
| Mar 31, 2021 | 15,732.00 |
| Mar 31, 2021 | 15,732.00 |
| Dec 31, 2020 | -1,000.00 |
| Dec 31, 2020 | -1,000.00 |
| Sep 30, 2020 | 3.56 Mn |
| Sep 30, 2020 | 3.56 Mn |
| Dec 31, 2019 | 2.33 Mn |
| Dec 31, 2019 | 2.33 Mn |